Express Healthcare
Home  »  News  »  SwasthVayu, ’Made in India’ non-invasive ventilator developed by National Aerospace Laboratories, Bengaluru

SwasthVayu, ’Made in India’ non-invasive ventilator developed by National Aerospace Laboratories, Bengaluru

0 1,645
Read Article

The Ethics Committee, scientific committee at Manipal Hospitals, Bengaluru has scrutinised, approved device for clinical trials under Dr Mysore

SwasthVayu is a ‘Made in India’ non-invasive ventilator being developed by the National Aerospace Laboratories (NAL), Bengaluru in scientific and medical knowledge collaboration with Dr Satyanarayana Mysore, HOD, Pulmonology Respiratory & Sleep Medicine, Lung Transplant Physician, Manipal Hospitals, Bengaluru and Dr Anurag Agarwal, Director of Council of Scientific and Industrial Research (CSIR) – Institute of Genomics and Integrative Biology (IGIB).

The National Aerospace Laboratories (NAL), a constituent of Council of Scientific and Industrial Research (CSIR), New Delhi, swung into action and took the challenge to develop SwasthVayu with clinical inputs from Dr Mysore and Dr Agarwal. SwasthVayu is equipped with advanced features like Bi-level mode (BiPAP), Continuous Positive Airway Mode (CPAP), Spontaneous modes and 3D printed HEPA-T filter adapter connected directly to the non-ventilated mask. “This is of paramount importance in minimising the risk of virus spread. The device also has a special provision to connect to the oxygen concentrator externally”, added Dr Mysore.

Dr CM Ananda, Chief Scientist and Head Electronics Division, NAL said that the device has been subjected to trials on artificial lung models and has successfully passed stringent electrical safety, performance, calibration, bio-compatibility tests at National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited laboratory. The device is registered with the Central Drug Research Institute (CDRI) and Central Drugs Standard Control Organisation (CDSCO) regulatory authorities. The device is ideal to treat patients with respiratory failure in both COVID and non-COVID situations, either in the ICU or non-intensive medical conditions. Further, this provides an opportunity for scarce ICU beds not to be overburdened and to be used for severely affected patients.

Dr Mysore further added, “Considering the nation’s endeavour of attaining self-reliance, indigenous production of this device, which for long had always been imported, is itself a mile stone.

The Ethics Committee, and the scientific committee at Manipal Hospitals, Bengaluru has scrutinised and approved the device for clinical trials under Dr Mysore.

Dr. Mysore further added that, “The device will also be a bonanza post-pandemic for treating sleep-disordered breathing including obstructive sleep apnoea and other sleep apnoea. The clinical trials will begin shortly and for now, the focus will be limited to the successful completion of the trials only.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image